French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.

Molecular mechanisms of TRPV4-mediated motor axon degeneration | Jeremy Sullivan, Ph.D. Efficient 4-factor induced Schwann (4FiS) cell platform for CMT1A modeling with macrophage-integrated neural ...

Correspondence to Georgios Koutsis, Neurogenetics Unit, 1st Department of Neurology, School of Medicine, Eginition Hospital, National and Kapodistrian University of Athens, Athens 11528, Greece; ...